SURMOUNT-5 Results: Tirzepatide Beats Semaglutide by 6.5% in Head-to-Head Weight Loss Trial
The first head-to-head trial comparing tirzepatide and semaglutide for obesity shows tirzepatide achieves 6.5 percentage points greater weight loss, establishing clear efficacy differences.
The question clinicians and patients have been asking since tirzepatide’s approval now has a definitive answer. SURMOUNT-5, the first head-to-head trial comparing tirzepatide (Zepbound/Mounjaro) to semaglutide (Wegovy/Ozempic) for weight loss, shows tirzepatide produces significantly greater weight reduction. The difference—6.5 percentage points—is clinically meaningful and statistically robust.
What We Know
SURMOUNT-5 enrolled approximately 750 adults with obesity or overweight with weight-related conditions, randomizing them to maximum tolerated doses of either tirzepatide (up to 15 mg weekly) or semaglutide (up to 2.4 mg weekly) for 72 weeks [surmount5-nejm]. Both medications were administered via once-weekly injection, and both groups received lifestyle counseling.
The primary endpoint was percent change in body weight from baseline. Tirzepatide-treated participants lost an average of 20.2% of their body weight, compared to 13.7% for semaglutide—a difference of 6.5 percentage points favoring tirzepatide. This difference was statistically significant with a p-value well below conventional thresholds.
Secondary outcomes also favored tirzepatide. A greater proportion of tirzepatide participants achieved clinically meaningful weight loss thresholds: more reached 10%, 15%, and 20% weight loss compared to semaglutide. Improvements in cardiometabolic parameters including blood pressure, lipids, and glycemic measures were generally greater with tirzepatide.
The magnitude of weight loss in both arms exceeded what has been achieved with previous obesity medications. Even the semaglutide arm showed impressive results by historical standards—the comparison here is between two highly effective treatments, not between an effective treatment and an inferior one.
Tirzepatide’s enhanced efficacy likely relates to its dual mechanism. While semaglutide acts solely on GLP-1 receptors, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP pathway contributes additional metabolic effects that appear to augment weight loss beyond GLP-1 stimulation alone.
Both medications were generally well-tolerated. Gastrointestinal side effects—nausea, diarrhea, constipation—were common in both groups, as expected for this medication class. Rates were numerically higher with tirzepatide but generally manageable, and discontinuation rates due to adverse events were similar between groups [lilly-press].
What We Don’t Know
While SURMOUNT-5 establishes efficacy differences, it cannot answer all clinically relevant questions. The trial lasted 72 weeks, so very long-term comparative outcomes and weight maintenance beyond this timeframe remain to be characterized.
Individual response variability is substantial with both medications. Some semaglutide users achieve results comparable to average tirzepatide outcomes, while some tirzepatide users have more modest responses. Population-level differences don’t predict individual results, and factors predicting response to one medication versus another are not well-defined.
The comparison was at maximum approved doses. Some patients cannot tolerate maximum doses due to side effects, and how lower doses compare between medications was not directly addressed. Real-world practice often involves dose adjustments based on tolerability.
Cost and access considerations are not captured in efficacy trials but profoundly affect real-world medication decisions. Both medications are expensive, and insurance coverage varies. Some patients may have access to one medication but not the other, making the head-to-head comparison less relevant for their individual decision.
Long-term safety comparison requires longer follow-up. While both medications have acceptable safety profiles, any differences in rare adverse events would only become apparent with extended use in larger populations.
What’s Next
Clinical practice guidelines are expected to incorporate SURMOUNT-5 findings. The American Gastroenterological Association and other organizations have published obesity pharmacotherapy guidelines that will likely be updated to reflect the comparative data [obesity-guidelines].
For clinicians, the results support tirzepatide as the more efficacious option when maximum weight loss is the primary goal and both medications are accessible. However, semaglutide remains a highly effective choice, particularly given its longer track record, established cardiovascular benefits, and potentially different side effect profile for some individuals.
Comparative effectiveness research in broader populations will supplement the trial data. Real-world evidence from insurance claims databases and electronic health records will show how the medications perform outside the controlled trial environment, in more diverse populations, and with varying adherence patterns.
Development continues for both medication classes. Higher doses of semaglutide are being studied, as are combination approaches and next-generation molecules. The competitive landscape will continue evolving, potentially reshaping these comparisons.
Cost-effectiveness analyses will help inform healthcare system decisions and coverage policies. Whether the additional weight loss achieved with tirzepatide justifies any cost premium, and how both medications compare to other interventions, will influence access and utilization.
How Strong Is the Evidence?
The evidence from SURMOUNT-5 is robust and reaches the “known” threshold for the specific question of comparative weight loss efficacy. The trial was randomized, double-blind, and appropriately powered. The effect size is large and statistically significant. The results align with biological expectations based on the dual mechanism of tirzepatide.
The New England Journal of Medicine publication and presentation at major medical conferences ensure the data has undergone rigorous peer review [surmount5-nejm]. The trial design, conduct, and analysis meet current standards for pivotal comparative effectiveness research.
What the trial does not establish is that tirzepatide is “better” for all patients or all outcomes. Weight loss is important but not the only consideration. Tolerability, cardiovascular outcomes, cost, access, patient preference, and individual response patterns all influence optimal medication selection.
For the practicing clinician, SURMOUNT-5 provides clear evidence to share with patients: tirzepatide produces more weight loss on average than semaglutide at maximum doses over 72 weeks. This information, combined with individual patient factors, cost considerations, and access realities, can inform shared decision-making.
The trial represents an important milestone in obesity pharmacotherapy—the first rigorous head-to-head comparison of the two leading medications. Both remain excellent options, and having comparative data helps optimize treatment selection for individuals seeking significant, sustained weight loss.
Sources & Citations
- 1
- 2
- 3regulatoryAGA Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity
obesity-guidelines
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.